THE USE OF THE FOLLOWING NOTATION IN THIS EXHIBIT INDICATES THAT A CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION: [***] SECOND...Second Collaboration and License Agreement • December 14th, 2016 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Second Collaboration And License Agreement (the “Agreement”) is entered into as of September 28, 2016 (the “Effective Date”) by and between (a) Amgen Inc. a Delaware corporation (“Amgen”) and (b) Arrowhead Pharmaceuticals, Inc., a Delaware corporation (“Arrowhead”). Arrowhead and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SECOND COLLABORATION AND LICENSE AGREEMENT (Muscular Dystrophy and Beta Thalassemia)Second Collaboration and License Agreement • August 9th, 2007 • Avi Biopharma Inc • Pharmaceutical preparations • Delaware
This Collaboration and License Agreement (the “Agreement”) between AVI BioPharma, Inc. of One S.W. Columbia, Suite 1105, Portland OR 97258 (“AVI”) and Ercole Biotech, Inc., of 7030 Kit Creek RD, Suite 150, Morrisville, NC (“Ercole”) is entered into and made effective this 1st day of May, 2007 (the “Effective Date”).
